Exploring the contribution of genetic variants to high sunitinib exposure in patients with cancer.
Eline L GiraudStefanie D KrensStefan BöhringerIngrid M E DesarSita H VermeulenLambertus A KiemeneyAlwin D R HuitemaNeeltje SteeghsNielka P van ErpJesse Joachim SwenPublished in: British journal of clinical pharmacology (2024)
While rs6923671 is associated with high sunitinib exposure, the underlying mechanism is not yet clarified and warrants further investigation. We could not confirm the earlier found associations between SNVs in candidate genes involved in the pharmacokinetic pathway of sunitinib and its efficacy and toxicity.